Total Pelvic Exenteration for Primary and Recurrent Malignancies

Floris Ferenschild(Erasmus MC Cancer Institute), Johannes H.W. de Wilt(Radboud University Nijmegen), Cornelis Verhoef(Erasmus MC Cancer Institute), Maarten Vermaas(Association of British Orchestras), Anca C. Ansink(Erasmus MC Cancer Institute), A.M.M. Eggermont(Praxis für Hämatologie und Onkologie), Wim J. Kirkels(Erasmus MC)

World Journal of Surgery

May 6, 2009

10.1007/s00268-009-0066-7

Cited by 193

Related Papers

The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes

|Cancer Cell|2020|683

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

|European Urology|2015|639

Body composition and outcome in patients undergoing resection of colorectal liver metastases19

|British journal of surgery|2012|464

Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial

|The Lancet. Gastroenterology & hepatology|2019|326

Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome

|Journal of Clinical Oncology|2003|321